Botox 200 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FJUY2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,544
Award facts
- Contract value 100% obligated
- $41,544.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $41,544 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of BOTOX 200 Unit Vials. The delivery order, issued on January 23, 2026, with an ultimate completion date of February 13, 2026, carries no set-aside designation, indicating the award was made through full and open competition. Performance will occur at the vendor's Park Ridge facility. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement across the Department of Defense.
As a prime vendor under the PPV-G GEN V program, DMS Pharmaceutical Group has demonstrated substantial capability in supplying a comprehensive range of pharmaceutical products and medical consumables to federal military healthcare facilities worldwide. The vendor's appointment represents the Defense Logistics Agency's effort to establish multiple regional prime vendor contractors capable of meeting the diverse and specialized pharmaceutical requirements of Department of Defense healthcare operations. This particular delivery order for BOTOX reflects routine pharmaceutical procurement activity under the broader $499.99 million IDC ceiling established in November 2025, which authorizes DLA to issue firm fixed-price orders through December 31, 2036.
Quick answers
Who was awarded contract SPE2DR26FJUY2?
SPE2DR26FJUY2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26FJUY2 worth?
The government has obligated $41,544 on SPE2DR26FJUY2.
Is contract SPE2DR26FJUY2 an order under another contract?
Yes. SPE2DR26FJUY2 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUY2 competed?
The extent of competition for SPE2DR26FJUY2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award